C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN, E9
Other Events
News, Material Contracts
BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
Announces First Quarter 2026 Financial Results and Business Updates
Annual Report to Security Holders
Files 2025 Annual Report with the STAR Market
Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership
End of Material Contract
Q1
FY 2024
Q3
Q2
Amended Annual Report
FY 2023
FY 2024 amended
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
S-4/A
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence
Automatic Shelf Registration Statement
Post-Effective Amendment to Registration Statement
S-8 POS